The MindBot project envisaged 3 phases:
Phase 1 - A comprehensive baseline assessment of the work experience was performed in manufacturing industries, taking into account the multiple facets of mental health, including psychological, psychosocial, physiological, environmental and organisational factors (WP2, WP3 and WP4).
Phase 2 – Development, testing and refinement of the innovative MindBot cobot platform (WP5 and WP6). The technologies for the final MindBot platform were developed, integrated and tested, before being delivered for their final assessment in a controlled laboratory environment.
Phase 3 – The MindBot prototype platform was tested in a controlled laboratory environment on neurotypical and autistic volunteers, in order to test and validate the system as regards workers’ mental health impact (WP7 and WP8).
Results of the project were the definition of an employment model for persons diagnosed with autism spectrum disorders (ASD) working in manufacturing companies adopting collaborative robots (Deliverable D7.2) and a description of all technical aspects and functional characteristics that should be taken into account for the realization of robotic cells that can promote operator well-being, in line with the concept of Industry 5.0 (Deliverable D7.3). The project also set organizational guidelines for the design of mental health friendly cobot workplaces. The guidelines will foster the need to promote worker’s mental well-being, which contribute to better company performance, and will pave the way toward new standards in designing that adopt collaborative robots in their production lines (Deliverable D8.2).
The MindBot project is included in the new Healthy Workplaces Campaign 2023-2025 “Safe and healthy work in the digital age” of the European Agency for Safety and Health at Work (EU-OSHA).
AMICO, a Multimodal device to improve inclusive Interaction between cobot and operator, developed within the MindBot project, recently won the first edition of the Life Science TTO Network Contest at the conference 'Future Trends in Translational Medicine' organised by the Human Technopole Foundation and Nature Italy.